Skip to main content

Biocon hits new high on DGCI nod to market Itolizumab for Covid treatment

Itolizumab will be manufactured and formulated as an intravenous injection at Biocon's bio-manufacturing facility at Biocon Park, Bengaluru

from Home Page https://ift.tt/2ZWKgCM

Comments

Popular posts from this blog